CTLA4 and metastatic melanoma: ICIs have revolutionized the treatment of advanced malignancies by enhancing T-cell-mediated immune responses against tumors, including Ipiplimumab, a CTLA-4 inhibitor, first approved for treatment of metastatic melanoma in 2011 [7,8]. However, their use is associated with a range of irAEs, among which endocrinopathies are both common and clinically significant [3]. The incidence of endocrine irAEs varies depending on the specific ICI used.